Skip to main content
SpringerLink
Log in

Aspirin and Other Antiplatelet Agents and Their Effects on Cardiovascular Disease in Type 2 Diabetes

  • Diabetes and Insulin Resistance (JB Meigs and M Rutter, Section Editors)
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Reduction of cardiovascular disease (CVD) events in patients with type 2 diabetes remains an area of intense interest and research. Recent trials of lower systolic blood pressure goals and combination lipid therapy have failed to show a significant reduction in CVD events in patients with diabetes. Antiplatelet agents are an additional option for CVD risk reduction in patients both with and without diabetes. However, two recent trials have questioned the role of aspirin in the primary prevention of CVD events in patients with diabetes. Although sub-analyses of larger trials have suggested a potential benefit of thienopyridine therapy in patients with diabetes, direct comparative trials are lacking and aspirin remains the appropriate first-line agent. Recent guidelines issued by the American Diabetes Association, American Heart Association, and American College of Cardiology Foundation on the use of aspirin for primary prevention in patients with diabetes remain the standard of practice. Two ongoing trials will help to address the question of the relative benefit of aspirin in patients with diabetes. The Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D) and A Study of Cardiovascular Events in Diabetes (ASCEND) are both randomized trials of 100 mg of aspirin compared to placebo and will enroll a combined 15,000 patients with diabetes between the two trials. Results may become available as soon as 2012.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164:1422–6.

    Article  PubMed  Google Scholar 

  2. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–94.

    Article  PubMed  CAS  Google Scholar 

  3. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150:405–10.

    PubMed  Google Scholar 

  4. • Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60. This latest update from the ongoing Oxford group Antithrombotic Trialists’ Collaboration contains not only excellent summaries of the published trials with aspirin therapy but also updates some of that previously published data using patient-level information obtained from the original trials. The accompanying online “webappendix” contains additional helpful information regarding the sub-analysis, including data comparing outcomes and bleeding events in patients with diabetes to those patients without diabetes.

    Article  PubMed  Google Scholar 

  5. • Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care. 2010;33:1395–402. This consensus statement from the three major organizations contains a meta-analysis on the use of aspirin that adds three additional trials to the ATT meta-analysis published in 2009 [4•]. Helpful discussion regarding the pharmacodynamics and pharmacokinetics of aspirin lend strength to the additional discussions on aspirin dosing and the concept of aspirin resistance.

    Article  PubMed  Google Scholar 

  6. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938–49.

    Article  PubMed  CAS  Google Scholar 

  7. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003;23:2131–7.

    Article  PubMed  CAS  Google Scholar 

  8. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–71.

    PubMed  CAS  Google Scholar 

  9. Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, Muller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost. 1998;80:1008–14.

    PubMed  CAS  Google Scholar 

  10. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378–84.

    Article  PubMed  CAS  Google Scholar 

  11. Colwell JA, Halushka PV, Sarji K, Levine J, Sagel J, Nair RM. Altered platelet function in diabetes mellitus. Diabetes. 1976;25:826–31.

    PubMed  CAS  Google Scholar 

  12. Davi G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002;288:2008–14.

    Article  PubMed  CAS  Google Scholar 

  13. Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32:525–7.

    Article  PubMed  CAS  Google Scholar 

  14. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med. 1990;322:1769–74.

    Article  PubMed  CAS  Google Scholar 

  15. Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets. 2006;17:577–85.

    Article  PubMed  CAS  Google Scholar 

  16. Desideri G, Ferri C. Effects of obesity and weight loss on soluble CD40L levels. JAMA. 2003;289:1781–2.

    Article  PubMed  Google Scholar 

  17. Weiss HJ, Aledort LM. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet. 1967;2:495–7.

    Article  PubMed  CAS  Google Scholar 

  18. Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res. 2004;113:101–13.

    Article  PubMed  CAS  Google Scholar 

  19. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54:2430–5.

    Article  PubMed  CAS  Google Scholar 

  20. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–5.

    Article  PubMed  CAS  Google Scholar 

  21. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 1983;67:1174–7.

    Article  PubMed  CAS  Google Scholar 

  22. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311:1206–11.

    Article  PubMed  CAS  Google Scholar 

  23. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–83.

    Article  PubMed  CAS  Google Scholar 

  24. • Roden DM, Stein CM. Clopidogrel and the concept of high-risk pharmacokinetics. Circulation. 2009;119:2127–30. Although not specific to patients with diabetes, this review offers excellent discussion and insight into the current debate surrounding the dosing of clopidogrel. Because this agent will be the first thienopyridine to reach generic status in the United States, a thorough understanding of when it is most appropriately used is essential to managing optimal antiplatelet regimens in the near future.

    Article  PubMed  Google Scholar 

  25. Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol. 2007;50:555–62.

    Article  PubMed  CAS  Google Scholar 

  26. Kleiman NS. Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel? J Am Coll Cardiol. 2008;51:1412–4.

    Article  PubMed  Google Scholar 

  27. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366–72.

    Article  PubMed  CAS  Google Scholar 

  28. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation. 2002;105:1620–2.

    Article  PubMed  Google Scholar 

  29. Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke. 1992;23:1400–3.

    Article  PubMed  CAS  Google Scholar 

  30. Cipollone F, Patrignani P, Greco A, et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation. 1997;96:1109–16.

    PubMed  CAS  Google Scholar 

  31. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet. 1999;353:900.

    Article  PubMed  CAS  Google Scholar 

  32. Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007;115:708–16.

    Article  PubMed  CAS  Google Scholar 

  33. Sibbing D, von Beckerath O, Schomig A, Kastrati A, von Beckerath N. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol. 2007;100:203–5.

    Article  PubMed  CAS  Google Scholar 

  34. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89:65–74.

    Article  PubMed  CAS  Google Scholar 

  35. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233–43.

    Article  PubMed  CAS  Google Scholar 

  36. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682–7.

    Article  PubMed  CAS  Google Scholar 

  37. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.

  38. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA. 1992;268:1292–300.

  39. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–41.

    Article  PubMed  CAS  Google Scholar 

  40. Saito Y, Morimoto T, Ogawa H, et al. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care. 2011;34:280–5.

    Article  PubMed  CAS  Google Scholar 

  41. Okada S, Morimoto T, Ogawa H, et al. Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. Diabetes Care. 2011;34:1277–83.

    Article  PubMed  CAS  Google Scholar 

  42. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.

    Article  PubMed  Google Scholar 

  43. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531.

    Article  PubMed  Google Scholar 

  44. Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract. 2010;87:211–8.

    Article  PubMed  CAS  Google Scholar 

  45. De Berardis G, Sacco M, Evangelista V, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007;8:21.

    Article  PubMed  Google Scholar 

  46. ASCEND. A study of cardiovascular events in diabetes.

  47. Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation. 1999;100:2477–84.

    PubMed  CAS  Google Scholar 

  48. King 3rd SB, Mahmud E. Will blocking the platelet save the diabetic? Circulation. 1999;100:2466–8.

    PubMed  Google Scholar 

  49. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol. 2003;41:966–8.

    Article  PubMed  Google Scholar 

  50. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet. 2000;355:337–45.

  51. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90:625–8.

    Article  PubMed  Google Scholar 

  52. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118:1626–36.

    Article  PubMed  CAS  Google Scholar 

  53. • Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097–105. This is the first prospective trial to publish results using surrogate platelet testing. Debate over the alteration of platelet function in patients with diabetes has fueled debate over platelet testing and individualation of antiplatelet regimens in this population. In the trial, 45% of patients had diabetes. Overall, the trial delivered disappointing results for the prospect of surrogate platelet testing. Patients receiving the higher dose of clopidogrel based on platelet testing did not have an improved outcome.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

C.D. Williams has received an “Investigator-initiated” grant (paid to his institution) from Merck. M.S. Kirkman reports no conflicts of interest relevant to this article.

Author information

Authors and Affiliations

  1. Oregon State University College of Pharmacy and Oregon Health and Science University School of Medicine, 3303 SW Bond Ave., CH12C, Portland, OR, 97239, USA

    C. D. Williams

  2. American Diabetes Association, 1701 N. Beauregard St., Alexandria, VA, 22311, USA

    M. S. Kirkman

Authors
  1. C. D. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. S. Kirkman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. D. Williams.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Williams, C.D., Kirkman, M.S. Aspirin and Other Antiplatelet Agents and Their Effects on Cardiovascular Disease in Type 2 Diabetes. Curr Cardiovasc Risk Rep 6, 62–70 (2012). https://doi.org/10.1007/s12170-011-0207-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12170-011-0207-z

Keywords

Search

Navigation